RYTHM, Inc. reported fourth‑quarter 2025 revenue of $7.0 million, driven almost entirely by licensing activity, and a gross margin of roughly 75%. The company posted an operating loss of $8.5 million, largely attributable to a non‑cash impairment charge that was recorded this quarter.
Quarter‑over‑quarter, licensing revenue surged 164% to $7.0 million from $2.8 million in Q3 2025, reflecting the rapid expansion of the company’s hemp‑derived THC portfolio and the growing demand for its branded beverages. The licensing model has become the primary revenue engine, replacing the legacy cultivation and extraction businesses that had previously dominated the company’s financials.
For the full year 2025, RYTHM generated $7.8 million in licensing revenue, up from $4.0 million in 2024, while total revenue for the year rose to $12.5 million, a 55% increase YoY. The jump is driven by the addition of new brands—Señorita, RYTHM, Dogwalkers, and others—and by a broader retail footprint that now includes more than 6,000 locations across 18 states, including over 800 Circle K stores.
The company’s strategic pivot away from cultivation and extraction toward hemp‑derived THC products and brand licensing is now evident in the financials. Licensing revenue now accounts for the majority of top‑line growth, and the company’s distribution network has expanded to support the new product lines. This shift is intended to position RYTHM as a leading player in the emerging THC beverage market, where it has already secured a foothold with its flagship brands.
The operating loss is largely a one‑time effect: an $8.5 million impairment charge was recorded to write down the value of certain assets that no longer align with the company’s new strategic focus. Excluding this charge, the company’s operating performance would have been profitable, underscoring that the underlying business model is generating positive cash flow and strong gross margins.
Management highlighted the transformation, noting that 2025 was a “transformational year” marked by a new name, ticker, and strategic direction. The company emphasized its confidence in the THC category and its ability to scale the licensing model, while acknowledging that the impairment charge is a necessary step to realign the balance sheet with the new business focus.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.